Captain T Cell

T cell–based therapies have made great progress in recent years, but targeting solid tumors still comes with a particular set of challenges, including tumor escape, a suppressive microenvironment, limited persistence, and the need to balance potency with safety. At this year’s 7th TCR-Based Therapies Summit in Boston, I’ll be co-hosting a workshop with Peggy Sotiropoulou from T-knife Therapeutics to discuss different engineering strategies for TCR-based therapies. I'll be also sharing how Captain T Cell is approaching these challenges in novel and innovative ways. Excited to be part of the Summit and look forward to insightful discussions!

Super proud to have been mentioned by Labiotech.eu! In their latest article on biotech companies to watch in 2026 Labiotech.eu highlights Captain T Cell alongside other innovative biotech companies from the Berlin and Brandenburg region. With our next-generation technologies for anticancer therapies and our best-in-class lead candidate advancing toward clinical validation, we are excited to contribute to Europe‘s growing biotech landscape. And yes, we absolutely agree – definitely one to watch 🚀 🗞️ – find the link to the article in the comments 

Recently, our CEO Felix Lorenz presented Captain T Cell at the Nuvisan Venture Capital Forum in Berlin, showcasing our strategy to next-generation TCR-T therapies and how we are advancing our innovations towards clinical validation. Turning bold science into real therapeutic application requires continuous dialogue within and beyond the biotech community, with potential investors and the right partners – this will create the right momentum needed to move forward! ↗️ 💡

Following BioLabs Investor Day in Paris, the next business stops are already ahead 🚀 📍BIO-Europe (March 23–25) and LSX Europe World Congress (March 25–26) in Lisbon Our CBO Till Erdmann will be on site representing Captain T Cell and engaging with investors, pharma partners, and potential collaborators!

We are very pleased to share that Captain T Cell has been selected to pitch at BioLabs European Investor Day in Paris on March 17! Our CBO Till Erdmann will represent the company and highlight our expanding pipeline of next-generation TCR-T innovations moving towards clinical validation. This event provides an opportunity to engage with leading investors and partners from across the European life sciences ecosystem. Till Erdmann will also be connecting with investors interested in supporting Captain T Cell's next stage of growth 🚀 – Looking forward to it!

Captain T Cell has been selected as one of the winners of the bio:cap Start-up Competition! 🚀 We are particularly happy about this recognition because bio:cap connects breakthrough science and experienced investors within the life sciences and AI ecosystem. At Captain T Cell, we are pioneering next-generation TCR-T therapies for cancer patients. While our autologous lead program is progressing toward the clinic, we are aiming to unlock off-the-shelf TCR therapies. Being recognized as innovators at an international investival like bio:cap means a great deal to us! Congrats as well to NeutroGen Therapeutics, our fellow Berlin-based innovators pioneering neutrophil transfusion therapies. Don’t miss it! 📅 – bio:cap in Berlin, 9-11 June 2026

🚉 next stop – next-generation 🚉 We love seeing Bayer Co.Labs new U-Bahn posters at U6 Reinickendorfer Straße in Berlin — an unconventional way to make science visible and highlight the startups turning ideas into real impact. At Captain T Cell , we’re proud to be part of this vibrant biotech community that supports us in bringing next-generation TCR-T therapies to patients. Thanks to the Bayer Co.Lab team for the visibility and the motivation boost on the way to the lab! And by the way: the U6 also stops right at Charité - Universitätsmedizin Berlin, where our lead candidate will enter a Phase I clinical trial soon. A coincidence...?